Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

BACKGROUND: Everolimus was recently introduced as a second-line treatment for renal cell carcinoma (RCC) and many other cancers. Several prospective studies have shown that serum creatinine levels are increased in a significant proportion of patients receiving everolimus. However, data on the occurr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Ha, Sung Hae, Park, Ji Hyeon, Jang, Hye Ryoun, Huh, Wooseong, Lim, Ho-Yeong, Kim, Yoon-Goo, Kim, Dae Joong, Oh, Ha Young, Lee, Jung Eun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265483/
https://ncbi.nlm.nih.gov/pubmed/25466872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-906
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak